Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of interest:
The state-led complex’s future evolution poses challenges for Brazil’s health system and domestic producers, as well as for western companies increasingly eager to tap into the country’s fast-growing healthcare sector while navigating its complex political environment with care.
Dealing with local and national governments, especially in the BRIC countries, will be the price that US/EU companies will have to pay in exchange for local market access.